22 months and counting. This may be the most promising case in the trial, so we still need to see what the other cases yielded, but that's still pretty good for a metastatic, resistant breast cancer. Does anyone see any potential downsides to the treatment besides cost? I'm thinking some sort of possible autoimmune response and the researchers' aforementioned concerns about the tumors evolving resistant proteins, but don't know precisely how big of a concern that is combined with the standard regimen.